127 related articles for article (PubMed ID: 38451815)
1. ALK upregulates POSTN and WNT signaling to drive neuroblastoma.
Huang M; Fang W; Farrel A; Li L; Chronopoulos A; Nasholm N; Cheng B; Zheng T; Yoda H; Barata MJ; Porras T; Miller ML; Zhen Q; Ghiglieri L; McHenry L; Wang L; Asgharzadeh S; Park J; Gustafson WC; Matthay KK; Maris JM; Weiss WA
Cell Rep; 2024 Mar; 43(3):113927. PubMed ID: 38451815
[TBL] [Abstract][Full Text] [Related]
2. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
3. Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate Cancer.
Unno K; Chalmers ZR; Pamarthy S; Vatapalli R; Rodriguez Y; Lysy B; Mok H; Sagar V; Han H; Yoo YA; Ku SY; Beltran H; Zhao Y; Abdulkadir SA
Cancer Res; 2021 Apr; 81(8):2157-2170. PubMed ID: 33637566
[TBL] [Abstract][Full Text] [Related]
4. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.
Berry T; Luther W; Bhatnagar N; Jamin Y; Poon E; Sanda T; Pei D; Sharma B; Vetharoy WR; Hallsworth A; Ahmad Z; Barker K; Moreau L; Webber H; Wang W; Liu Q; Perez-Atayde A; Rodig S; Cheung NK; Raynaud F; Hallberg B; Robinson SP; Gray NS; Pearson AD; Eccles SA; Chesler L; George RE
Cancer Cell; 2012 Jul; 22(1):117-30. PubMed ID: 22789543
[TBL] [Abstract][Full Text] [Related]
5. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
[TBL] [Abstract][Full Text] [Related]
6. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE
Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590
[TBL] [Abstract][Full Text] [Related]
7. Generation of conditional ALK F1174L mutant mouse models for the study of neuroblastoma pathogenesis.
Ono S; Saito T; Terui K; Yoshida H; Enomoto H
Genesis; 2019 Oct; 57(10):e23323. PubMed ID: 31218818
[TBL] [Abstract][Full Text] [Related]
8. ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation.
Borenäs M; Umapathy G; Lai WY; Lind DE; Witek B; Guan J; Mendoza-Garcia P; Masudi T; Claeys A; Chuang TP; El Wakil A; Arefin B; Fransson S; Koster J; Johansson M; Gaarder J; Van den Eynden J; Hallberg B; Palmer RH
EMBO J; 2021 Feb; 40(3):e105784. PubMed ID: 33411331
[TBL] [Abstract][Full Text] [Related]
9. The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line.
Yi B; Yang J; Wang L
Tumour Biol; 2014 Apr; 35(4):3229-35. PubMed ID: 24293393
[TBL] [Abstract][Full Text] [Related]
10. Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis.
Lopez-Delisle L; Pierre-Eugène C; Louis-Brennetot C; Surdez D; Raynal V; Baulande S; Boeva V; Grossetête-Lalami S; Combaret V; Peuchmaur M; Delattre O; Janoueix-Lerosey I
Oncogene; 2018 Mar; 37(11):1417-1429. PubMed ID: 29321660
[TBL] [Abstract][Full Text] [Related]
11. ALK(R1275Q) perturbs extracellular matrix, enhances cell invasion and leads to the development of neuroblastoma in cooperation with MYCN.
Ueda T; Nakata Y; Yamasaki N; Oda H; Sentani K; Kanai A; Onishi N; Ikeda K; Sera Y; Honda ZI; Tanaka K; Sata M; Ogawa S; Yasui W; Saya H; Takita J; Honda H
Oncogene; 2016 Aug; 35(34):4447-58. PubMed ID: 26829053
[TBL] [Abstract][Full Text] [Related]
12. The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.
Guan J; Tucker ER; Wan H; Chand D; Danielson LS; Ruuth K; El Wakil A; Witek B; Jamin Y; Umapathy G; Robinson SP; Johnson TW; Smeal T; Martinsson T; Chesler L; Palmer RH; Hallberg B
Dis Model Mech; 2016 Sep; 9(9):941-52. PubMed ID: 27483357
[TBL] [Abstract][Full Text] [Related]
13. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
[TBL] [Abstract][Full Text] [Related]
14. ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma.
Hasan MK; Nafady A; Takatori A; Kishida S; Ohira M; Suenaga Y; Hossain S; Akter J; Ogura A; Nakamura Y; Kadomatsu K; Nakagawara A
Sci Rep; 2013 Dec; 3():3450. PubMed ID: 24356251
[TBL] [Abstract][Full Text] [Related]
15. The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma.
Umapathy G; El Wakil A; Witek B; Chesler L; Danielson L; Deng X; Gray NS; Johansson M; Kvarnbrink S; Ruuth K; Schönherr C; Palmer RH; Hallberg B
Sci Signal; 2014 Oct; 7(349):ra102. PubMed ID: 25351247
[TBL] [Abstract][Full Text] [Related]
16. ALK expression, prognostic significance, and its association with MYCN expression in MYCN non-amplified neuroblastoma.
Somasundaram DB; Aravindan S; Gupta N; Yu Z; Baker A; Aravindan N
World J Pediatr; 2022 Apr; 18(4):285-293. PubMed ID: 35132576
[No Abstract] [Full Text] [Related]
17. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis.
Zhu S; Lee JS; Guo F; Shin J; Perez-Atayde AR; Kutok JL; Rodig SJ; Neuberg DS; Helman D; Feng H; Stewart RA; Wang W; George RE; Kanki JP; Look AT
Cancer Cell; 2012 Mar; 21(3):362-73. PubMed ID: 22439933
[TBL] [Abstract][Full Text] [Related]
18. Wild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and initiate tumor formation in murine neural crest progenitor cells.
Montavon G; Jauquier N; Coulon A; Peuchmaur M; Flahaut M; Bourloud KB; Yan P; Delattre O; Sommer L; Joseph JM; Janoueix-Lerosey I; Gross N; Mühlethaler-Mottet A
Oncotarget; 2014 Jun; 5(12):4452-66. PubMed ID: 24947326
[TBL] [Abstract][Full Text] [Related]
19. ALK pERKs up MYCN in neuroblastoma.
Lindner S; Henssen A; Astrahantseff K; Schulte JH
Sci Signal; 2014 Oct; 7(349):pe27. PubMed ID: 25351246
[TBL] [Abstract][Full Text] [Related]
20. Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.
Cazes A; Lopez-Delisle L; Tsarovina K; Pierre-Eugène C; De Preter K; Peuchmaur M; Nicolas A; Provost C; Louis-Brennetot C; Daveau R; Kumps C; Cascone I; Schleiermacher G; Prignon A; Speleman F; Rohrer H; Delattre O; Janoueix-Lerosey I
Oncotarget; 2014 May; 5(9):2688-702. PubMed ID: 24811913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
